Patents Assigned to Genentech
  • Anti-Jagged1 Antibodies and Methods of Use
    Publication number: 20240384000
    Abstract: The invention provides anti-Jagged1 antibodies and methods of using the same.
    Type: Application
    Filed: January 18, 2024
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 12145997
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: April 26, 2024
    Date of Patent: November 19, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Pertuzumab variants and evaluation thereof
    Patent number: 12145998
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: November 19, 2024
    Assignee: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Bicyclic pyridone lactams and methods of use thereof
    Patent number: 12139482
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventor: Snahel Patel
  • Therapeutic compounds and methods of use thereof
    Patent number: 12139496
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
  • Pathological response calculation and assessment tool
    Patent number: 12141968
    Abstract: In one embodiment, a method includes, for each of a set of samples, receiving data input that includes dimensions of a sample area, a percentage of the sample area being viable cells, and a percentage of the sample area exhibiting necrosis. The method includes, for each of the set of samples, computing a percentage of the sample area being stroma. The method includes, for each of the set of samples, computing weighting factors. The method includes computing a weighted percentage of the set of samples being viable cells based on the computed weighting factor and percentage of the sample area being viable cells for each of the set of samples. The method includes determining that a specified condition is detected in the set of samples based on the computed weighted percentage of the set of samples being viable cells satisfying a threshold correlating with an indication of the specified condition.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Anjali Saqi, Shawn Wen Sun, Kosei Tajima, Barbara Jennifer Gitlitz
  • CINNOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20240368170
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: July 10, 2024
    Publication date: November 7, 2024
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • ANTI-POLYUBIQUITIN MULTISPECIFIC ANTIBODIES
    Publication number: 20240369575
    Abstract: Multispecific antibodies comprising a first half antibody comprising a first antigen binding site that binds to a polyubiquitin; and a second half antibody comprising a second antigen binding site that binds a pro-inflammatory protein, such as receptor-interacting protein kinase 1 (RIP1) or receptor-interacting protein kinase 2 (RIP2), as well as methods for using the antibodies, are provided.
    Type: Application
    Filed: February 26, 2024
    Publication date: November 7, 2024
    Applicant: Genentech, Inc.
    Inventors: Marissa Lynn MATSUMOTO, Domagoj VUCIC, Tatiana GONCHAROV
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 12134649
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 5, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • OVARIAN TOXICITY ASSESSMENT IN HISTOPATHOLOGICAL IMAGES USING DEEP LEARNING
    Publication number: 20240362784
    Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.
    Type: Application
    Filed: July 12, 2024
    Publication date: October 31, 2024
    Applicant: GENENTECH, INC.
    Inventor: Fang-Yao HU
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 12128103
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: October 29, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Targeted integration of nucleic acids
    Patent number: 12129480
    Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 29, 2024
    Assignee: GENENTECH, INC.
    Inventors: Chi Kin Domingos Ng, Yongping Guo Crawford, Amy Shen, Meixia Zhou, Bradley R. Snedecor, Shahram Misaghi, Albert Eric Gao
  • Optimized variants of anti-VEGF antibodies
    Patent number: 12121586
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 22, 2024
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • METABOLOMIC ANALYSIS
    Publication number: 20240344013
    Abstract: Provided herein are methods for quantifying the concentration of multiple metabolites in a sample. Also provided are methods for relative quantification of multiple metabolites in a sample, methods for monitoring the course of a cell culture, and methods for optimising a cell culture.
    Type: Application
    Filed: March 13, 2024
    Publication date: October 17, 2024
    Applicant: Genentech, Inc.
    Inventors: Zijuan LAI, Shahram MISAGHI, Dewakar SANGARAJU, Danming TANG
  • Deep convolutional neural networks for tumor segmentation with positron emission tomography
    Patent number: 12115015
    Abstract: The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: October 15, 2024
    Assignee: GENENTECH, INC.
    Inventors: Nils Gustav Thomas Bengtsson, Richard Alan Duray Carano, Alexander James Stephen Champion de Crespigny, Jill Osborn Fredrickson, Mohamed Skander Jemaa
  • SULFONIMIDAMDE COMPOUNDS AND USES THEREOF
    Publication number: 20240336625
    Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.
    Type: Application
    Filed: July 15, 2022
    Publication date: October 10, 2024
    Applicant: Genentech, Inc.
    Inventors: Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Craig STIVALA
  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240336697
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.
    Type: Application
    Filed: August 2, 2022
    Publication date: October 10, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Calvin Ka Yin LEE, Huan JIN, Lijia WANG, Jiaheng QIU, Qingxiang YAN
  • Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
    Patent number: 12110341
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: April 19, 2024
    Date of Patent: October 8, 2024
    Assignee: Genentech, Inc.
    Inventors: Reed J. Harris, Paul A. Motchnik
  • Pyrazolo compounds and methods of use thereof
    Patent number: 12110276
    Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: October 8, 2024
    Assignee: GENENTECH, INC.
    Inventors: Jason Robert Zbieg, Russell Tyler Smith, Paul Powell Beroza, Vishal Anil Verma, Bing-Yan Zhu, Ramsay Beveridge, Lisa Marie Barton, Bryan Ka Ip Chan, Curtis Colwell, Samir Bouayad-Gervais, Anwesha Dey, Marie Anne Evangelista
  • STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
    Publication number: 20240325559
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Ankit R. PATEL, Jun LIU